Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Interferon-alpha
  • Kidney Neoplasms
  • Sirolimus

abstract

  • The combination of temsirolimus and IFN has an acceptable safety profile and displays antitumor activity in patients with advanced RCC. Temsirolimus 15 mg plus IFN 6 MU is the recommended dose for evaluation in a randomized phase III study.

publication date

  • September 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.10.5916

PubMed ID

  • 17761980

Additional Document Info

start page

  • 3958

end page

  • 64

volume

  • 25

number

  • 25